0001630176 false 0001630176 2026-11-10 2026-11-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported):

 

November 10, 2026

 

HEALTHY EXTRACTS INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

000-55572

 

47-2594704

(State or other
jurisdiction of incorporation)

 

(Commission
File Number)

 

(I.R.S. Employer
Identification No.)

 

 

 

 

 

 

 

 

 

 

7375 Commercial Way, Suite 125

Henderson, NV 89011

(Address of principal executive offices) (zip code)

 

 

 

 

 

(702) 463-1004

(Registrant’s telephone number, including area code)

 

 

 

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ¨


Section 1 – Registrant’s Business and Operations

 

Item 1.01   Entry into a Material Definitive Agreement.

 

On November 10, 2026, we entered into a Securities Purchase Agreement whereby we issued a Secured Promissory Note in the principal amount of $555,556 to HINTERLAND PARTNERS LLC, a Delaware limited liability company (the “Holder”). The Note has an original issue discount of $55,556, a maturity date of thirty (30) months from the issue date, and bears interest at the rate of thirteen percent (13%) per annum. If any amount of the Note is outstanding on the 181st day after the issue date, on November 10, 2027, or on November 10, 2028, an additional twelve (12) months of interest (equal to $60,185.23) is guaranteed and earned in full on each such date, and all accrued interest is waived if the Note is repaid in full within 90 days after the issue date. We received a net amount of $459,500 upon issuance of the Note, after the Holder withheld $5,500 for its legal fees, $5,000 for its due diligence costs, and $30,000 for Carter, Terry, & Company, Inc., the placement agent. The Note may not be prepaid except as provided in the Note, which permits prepayment on five (5) trading days’ notice prior to an event of default. The Note is convertible at a fixed conversion price of $2.00 per share, subject to adjustment, provided that following an event of default the conversion price is the lesser of $2.00 per share or the market price (as defined in the Note). Beginning March 1, 2027, and on the first business day of each month thereafter until the Note is extinguished, we are further required to make royalty payments equal to 12.5% of our gross revenue for the preceding month, which are applied first to accrued interest and then to principal. Upon an event of default, the Note becomes immediately due and payable at 150% of the outstanding principal and accrued interest. 

 

In connection with the Note, we and our subsidiaries entered into a Security Agreement dated November 10, 2026 with the Holder, pursuant to which we and our subsidiaries granted the Holder a security interest in substantially all of our assets to secure our obligations under the Note. The Security Agreement automatically terminates upon the initial listing of our common stock on any tier of the NASDAQ Stock Market, the New York Stock Exchange, or the NYSE American. 

 

Section 3 – Securities and Trading Markets

 

Item 3.02Unregistered Sale of Equity Securities. 

 

The disclosure in Item 1.01 above regarding the issuance of the Note is incorporated herein by reference.  

 

The Note and the shares of common stock issuable upon conversion of the Note sold pursuant to the Securities Purchase Agreement were offered and sold in reliance on an exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. The investor is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D and has acquired the securities for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof. The securities were not issued through any general solicitation or advertisement.


2


 

Section 9 – Financial Statements and Exhibits.

 

Item 9.01Financial Statements and Exhibits. 

 

(d)Exhibits 

 

10.1

 

Securities Purchase Agreement dated November 10, 2026

10.2

 

Secured Promissory Note dated November 10, 2026

10.3

 

Security Agreement dated November 10, 2026


3


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

 

 

 

Healthy Extracts Inc.

 

 

 

 

Dated: November 13, 2026

/s/ Donald Swanson

 

By:Donald Swanson 

 

Its:Chief Executive Officer 


4